Robert Negrin, MD, is president of the American Society of Hematology and a professor of medicine at Stanford University. 

Looking Ahead to ASH’s 68th Meeting, With President Robert Negrin, MD

 recently wrapped its 67th Annual Meeting and Exposition in Orlando, Florida, with > 8,200 abstracts accepted and > 1,100 oral presentations, exemplifying the expansive nature of the 

“The science was spectacular,” said Robert Negrin, MD, newly elected president of ASH and professor of medicine at Stanford University, in an interview with 

That goes without saying. I think that's something that happens every year, but I would say that the late-breaking abstract session was probably the best session I've ever attended. Every paper was practice-changing or groundbreaking.

At the 67th ASH meeting, investigators highlighted in vivo CAR T therapies, next-generation autologous and allogeneic CAR T platforms, and novel bispecific antibodies, chemotherapy combinations improving outcomes in myeloma and other hematologic diseases. Key data included the Phase 2 iMMagine‑1 trial of anitocabtagene autoleucel, the phase 3 MajesTEC‑3 trial of teclistamab with anti‑CD38 therapy, a phase 2 cevostamab post-CAR T study, early Durga‑1 results on AZD0120, extended ELARA follow-up on tisagenlecleucel, and updates from CARTITUDE‑4 and the COBRA trial.

These findings reinforce a rapidly evolving hematology landscape, demonstrating the impact of CAR T therapies, next-generation platforms, and bispecific antibody combinations can deliver deeper, more durable responses in myeloma and lymphoma. They signal potential shifts in standard care, expand treatment options for relapsed or refractory patients, and highlight the promise of personalized, multi-antigen strategies to improve outcomes across hematologic diseases.

Negrin has been involved in the organization since he attended his first meeting as a fellow in the 1990s. In his 33 years as a member, he served as the inaugural editor-in-chief of 

, as an ad hoc member of the Executive Committee, and as chair of the Scientific Committee on Transplant Biology and Cellular Therapies.

“Many people describe ASH as their scientific family, and that is something the leadership should take great pride in. For me personally, it’s been an opportunity to contribute through various committees, journals, and now the executive committee,” remarked Negrin. “It is vital that we demonstrate to our community that ASH will continue to enrich opportunities and experiences for its members worldwide.”

Over his career, Negrin’s research has focused on understanding and improving the biology of immune responses after bone marrow and stem cell transplants, including the balance between graft‑versus‑host disease and graft‑versus‑tumor effects using animal models and clinical studies. Additionally, he has been involved in investigating how specific immune cell populations influence graft outcomes and immunotherapy, including work on cytotoxic T cells and regulatory T cells to improve transplant success and reduce complications.

Looking ahead, the 68th Annual Meeting and Exposition will take place December 12–15, 2026, in New Orleans, Louisiana.

“I’m also really excited about going to New Orleans. It’s a fantastic city, and the meeting will be buzzing with activity. There are so many highlights in the annual program, and I can’t give all the secrets away, you have to be there to experience it. But most importantly, the meeting reinforces a sense of community, which I think is critical.”

Editor’s note: Negrin reports relevant disclosures with BioEclipse Therapeutics, Biorasi, Amgen, and others.

Highlights of ASH in North America - Hematology.org. Hematology.org. Published 2026. Accessed January 27, 2026. 

https://www.hematology.org/meetings/highlights-of-ash-in-north-america

Robert Negrin MD Begins Term as 2026 ASH President - Hematology.org. Hematology.org. Published 2026. Accessed January 27, 2026. https://www.hematology.org/newsroom/press-releases/2026/robert-negrin-md-begins-term-as-2026-ash-president
‌Negrin Lab. Blood & Marrow Transplantation& Cellular Therapy Division. Published 2020. Accessed January 27, 2026. 

https://med.stanford.edu/bmt/research/negrin-lab.html

Videos

ASH’s new president, Robert Negrin, explains key takeaways from the 67th meeting and sets the scene for ASH 2026. 


Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Hematology

Acne and Rosacea Treatment Updates for 2026, With Lawrence Eichenfield, MD

, a session was presented titled ‘Acne and Rosacea: Update 2026,’ featuring a discussion of challenging case scenarios and new insights into acne and rosacea treatment paradigms.

This session was presented by several speakers, 1 of whom was Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics at the UC San Diego School of Medicine. Eichenfield sat down with 

 to discuss takeaways from his acne and rosacea talk.

“There have been some new data that have come up,” Eichenfield stated. “There are questions that have remained in relation to isotretinoin in patients that come up all the time in practice. So I went through some of the data on them, especially the new data.”

Eichenfield noted recent, well-designed studies have come out suggesting isotretinoin does not adversely impact height among pediatric patients, addressing longstanding concerns some have expressed regarding premature epiphyseal closure. He also touched on evidence supporting cumulative dosing, rather than daily dose intensity, as the key element affecting the likelihood of relapse or need for repeat courses.

Additionally, Eichenfield spoke about updates related to hormonal therapies in acne. In particular, he spoke on the evolving guidelines related to oral contraceptive use in teenage adolescents with acne. Eichenfield pointed to forthcoming recommendations suggesting avoidance of oral contraceptives for acne treatment in individuals under the age of 16 years until they are at least 2 years post-menarche, given considerations around bone mineral density and pubertal development.

“That's a balance of the need for the treatment of acne with things like bone mineral density, where 90% of that happens up to the adolescent time period, as well as general pubertal health,” Eichenfield said. “And there are exceptions that are made if there are other conditions [such as] abnormal uterine bleeding, [polycystic ovary syndrome] syndrome that might give a reason to use OCPs for acne, plus other conditions.”

In the therapeutic realm, Eichenfield reinforced the continued central role of topical medications, highlighting strong study findings supporting the implementation of triple-combination topical treatments as highly effective monotherapies. These drugs, he noted, may be capable of diminishing one’s reliance on oral antibiotics. He addressed concerns about antibiotic resistance, highlighting data suggesting benzoyl peroxide–containing combinations mitigate this risk.

Eichenfield also spoke about newer hormonal approaches, noting certain topical agents can reduce sebum production. He reaffirmed isotretinoin’s role as a reliable “backstop” therapy capable of attaining near-universal clearance in those with severe acne.

For more news on recent trial data and insights into various dermatologic diseases, view 

The quotes used in this interview summary were edited for clarity.

Disclosures: Eichenfield previously reported receiving personal fees from Pfizer Inc; grant funding from AbbVie, Arcutis Biotherapeutics, Bausch + Lomb, Castle Biosciences, Dermavant Sciences Inc, Galderma SA, Pfizer Inc, Regeneron, and Sanofi SA and consulting for ASLAN Pharmaceuticals, AbbVie, Almirall, SA, Arcutis Biotherapeutics, Arena Pharmaceuticals Inc, Dermavant Sciences Inc, Galderma SA, Incyte Corporation, LEO Pharma A/S, Eli Lilly and Company, Ortho Dermatologics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi SA, and UCB; and serving on the board of directors of Forté Pharma.

Eichenfield L, Harper J, Baldwin H. Acne and Rosacea: Update 2026. Presented at: Maui Derm Hawaii 2026; January 25-29, 2026; Maui, Hawaii.

Picardo M, Eichenfield LF, Tan J. Acne and Rosacea. Dermatol Ther (Heidelb). 2017 Jan;7(Suppl 1):43-52. doi: 10.1007/s13555-016-0168-8. Epub 2017 Feb 1. PMID: 28150107; PMCID: PMC5289119.

This interview from the Maui Derm 2026 conference features Lawrence Eichenfield, MD, discussing takeaways from his talk ‘Acne and Rosacea: Update 2026.’

Acne

The HCPLive acne page is a resource for medical news and expert insights on dermatological disease. This page features expert-led coverage, articles, videos, and research on the therapies and development of treatments for chronic acne, and more.

Rosacea

On the HCPLive rosacea page, resources on the topics of medical news and expert insight into acne rosacea can be found. Content includes articles, interviews, videos, podcasts, and breaking news on the skin condition, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

David Golden, MD, clinical associate professor of medicine at Johns Hopkins University School of Medicine.

Anticipating The FDA Decision of Anaphylm for Anaphylaxis, With David Golden, MD

 date for epinephrine sublingual film (Anaphylm) in the treatment of 

 spoke with investigator David Golden, MD, clinical associate professor of medicine at the Johns Hopkins University School of Medicine, about how this novel formulation compares with epinephrine autoinjectors and the clinical relevance of the oral allergy syndrome challenge that supported the New Drug Application (NDA).

According to Golden, the median time to symptom resolution was 15.1 minutes with sublingual epinephrine film, versus 74 minutes without.

“We like the fact that Anaphylm works very rapidly, as fast as the auto injector,” Golden said.

He continued, saying that many doctors in hospitals or clinics administer epinephrine by manual injection rather than an auto-injector. However, manual epinephrine injections do not work as quickly as epinephrine sublingual film or autoinjectors. 

“That's one of the nice things that we can say about Anaphylm,” Golden added.

The NDA package included positive results from an oral allergy syndrome challenge, which found that allergic reaction symptoms resolved 2 minutes after epinephrine sublingual film administration.

 Epinephrine sublingual film, a polymer matrix-based epinephrine prodrug product candidate for anaphylaxis that weighs less than an ounce, showed promise in 11 independent clinical studies, encompassing approximately 967 administrations across 411 participants. At 10 minutes after epinephrine sublingual film administration, pediatric patients and adults had mean baseline-adjusted epinephrine concentrations over time of approximately 280 pg/mL and 330 pg/mL, respectively.

“I’m a big fan of having choices, and I don't think any 1 [treatment] is the right thing for everyone,” Golden said. “I have patients who will want to and should probably just continue to have auto injector prescriptions, and some people don't exactly love nasal spray, so they may want to try a sublingual film. Some people will find it more portable to carry the sublingual film. Again, it actually addresses a number of the problems that keep people from carrying it and using it and has some advantages that will appeal to many people, but I think there's a place for every one of those products.”

Brooks A. FDA Accepts Epinephrine (Anaphylm) Sublingual Film NDA for Type 1 Allergic Reactions. HCPLive. Published on June 19, 2025. Accessed on January 22, 2026.

 https://www.hcplive.com/view/fda-accepts-epinephrine-anaphylm-sublingual-film-nda-type-1-allergic-reactions

Derman C. Aquestive’s Anaphylm for Severe Allergic Reactions Shows Promise in Children. HCPLive Published on April 1, 2025. Accessed January 22, 2026.

 https://www.hcplive.com/view/aquestive-s-anaphylm-for-severe-allergic-reactions-shows-promise-in-children

As the January 31 PDUFA date approaches, Golden discusses that epinephrine sublingual film may deliver symptom relief as rapidly as autoinjectors, with added portability.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Andrew Kau, MD, PhD, is an associate professor in the John T. Milliken Department of Medicine at WashU Medicine.

Audrey John, MD, PhD, is chief of the division of Pediatric Infectious Diseases at Children's Hospital of Philadelphia.

Exploring Exhaled Breath as a New Platform for Gut Microbiome-Based Diagnostics

Despite being one of the most accessible biological samples clinicians can obtain, exhaled breath contains a complex molecular signature that reflects processes occurring throughout the body. Growing interest in breath-based diagnostics has raised new questions about what these chemical signals truly represent and where they originate.

Emerging research links exhaled breath to the gut microbiome, offering insight into how microbial metabolism in the intestine may shape the volatile compounds detected in different parts of the body and how this connection could ultimately support new, noninvasive ways to assess health and disease.

“I think one of the questions that we've been aware of for a while is that we know that these metabolites that are produced by gut microbes circulate throughout the body,” senior study author Andrew Kau, MD, PhD, an associate professor in the John T. Milliken Department of Medicine at WashU Medicine, told 

. “We came into this study asking if those metabolites actually show up in the breath, and is that something that we could use to look and see what the activity of gut microbes are in that moment.”

A single breath sample can contain hundreds of volatile organic compounds (VOCs), many of which have already been linked to infectious, metabolic, and inflammatory diseases. What has remained unclear is the origin of many of these compounds and to what extent gut microbes contribute to what clinicians measure in exhaled breath.

While Kau noted that prior work had already established communication between the gut and lung, as well as the ability of microbial metabolites to circulate systemically, he said what had not been rigorously tested was whether those gut-derived metabolites could be reliably detected in breath, and whether breath could serve as a real-time readout of microbial activity. To address this, investigators evaluated the question across multiple experimental systems, including mice, humans, and in vitro models.

“We went in testing this idea that gut microbes could directly contribute compounds that would show up in breath. While we showed that that is the case, we also showed that there's probably lots of other ways in which gut microbes influence the volatiles we see in the breath,” Kau said. “To me, that was a little bit surprising, and it's something that we're very interested in potentially following up on.”

In the study, they analyzed the breath and stool of 27 healthy children for microbe-derived compounds and gut microbes, respectively, and found that the compounds in the children’s breath matched the compounds known to be produced by the very microbes present in their stool. Of note, investigators obtained similar results in mice by transplanting bacteria into animals without gut microbes of their own and finding that gut bacteria can be identified from breath compounds.

Researchers additionally compared breath and stool samples from healthy children to samples from children with asthma and found that breath samples from children with asthma could predict the presence of 

Both experts underscored the potential clinical implications of this work. John described particular interest in neonatal care, where early microbial changes in the gut often precede bloodstream infections in premature infants. A breath-based approach could, in principle, allow clinicians to detect risk earlier and intervene before disease onset. Kau echoed this vision, pointing to broader applications in conditions linked to gut dysbiosis, such as malnutrition and allergic disease.

At the same time, the researchers acknowledged key challenges ahead.

“I think one of the ones that we're going to have to struggle with, and probably have to study specifically, is the impact of diet,” study author Audrey John, MD, PhD, Chief of the Division of Pediatric Infectious Diseases at Children's Hospital of Philadelphia, said. “We know that some of what you're seeing in the breath is coming from what people eat, and that obviously diet also influences the microbes themselves, so understanding to what degree the breath is influenced by the diet and in what ways the breath is influenced by the diet is going to be an important barrier.”

Diet and environmental exposures, they agreed, will need to be carefully studied, as both can influence breath composition and microbial behavior. Even so, both see breath analysis as a promising bridge between microbiome science and practical, point-of-care diagnostics that could make complex microbial insights far more accessible in clinical settings.

Editors’ Note: Kau reports relevant disclosures with Ancilia Biosciences, Inimune, NIH, and Doris Duke Charitable Foundation. John reports relevant disclosures with Pluton Biosciences, NIH, Department of Defense, USDA, Doris Duke Charitable Foundation, and the Bill and Melinda Gates Foundation.

WashU Medicine. Breath carries clues to gut microbiome health. EurekAlert! 

https://www.eurekalert.org/news-releases/1112879

Hernandez-Leyva AJ, Berna AZ, Bui MH, et al. The gut microbiota shapes the human and murine breath volatilome. 

Andrew Kau, MD, PhD, and Audrey John, MD, PhD, discuss their recent research exploring exhaled breath analysis as a noninvasive way to probe the gut microbiome.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Levi Garraway, MD, PhD | Image Credit: Precision Medicine World Conference 2026

On January 27, 2026, Genentech, a member of the Roche Group, announced positive topline results from the phase 2 CT388-103 trial, which investigated CT-388 for the treatment of 

CT-388 is an investigational dual GLP-1/GIP receptor agonist, designed for once-weekly subcutaneous administration in patients with 

, obesity, and other obesity-related comorbidities. The drug aims to regulate blood sugar and reduce appetite by targeting and activating receptors which integrate nutrient-derived signals to control energy homeostasis.

“We are pleased to see such meaningful weight loss in people treated with CT-388,” Levi Garraway, MD, PhD, chief medical officer and head of global product development for Genentech, said in a statement. “The robust weight loss combined with a well-tolerated safety profile reinforces our confidence in the clinical development program as we advance to phase 3 trials.”

The CT388-103 trial was a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study aiming to evaluate the safety and efficacy of CT-388 at low, middle, and high doses. To be eligible for inclusion, patients were required to be 18-75 years of age with a body mass index (BMI) ≥30 kg/m2, or a BMI ≥27 and <30 kg/m2 and a previous diagnosis of >1 from among prediabetes, 

Patients were excluded from the trial if they had a prior history of any type of diabetes mellitus, or a self-reported body weight change of >5 kg within 3 months before randomization. Additionally, patients were excluded if they had undergone any unbalanced or extreme diets within 3 months of screening or surgical treatment for obesity, among other criteria.

CT388-103’s primary endpoint was the percent change in body weight from baseline to week 48. Secondary outcomes include the percentage of participants with body weight reduction ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% from baseline to week 48, as well as absolute change in body weight, change in BMI from baseline, and change in waist circumference from baseline, among other endpoints.

A total of 469 patients were enrolled in the trial and randomly assigned to either CT-388 at 1 of 5 doses (up to 24 mg) administered once weekly or matching placebo. Over 48 weeks, investigators observed a clear dose-response relationship on weight loss, as once-weekly injections of CT-388 resulted in placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a plateau. For the treatment-regimen estimand, CT-388 achieved placebo-adjusted weight loss of 18.3% (

At week 48 for the highest does (24 mg), 95.7% of patients receiving CT-388 achieved a weight loss of ≥5%, 87% achieved ≥10%, 47.8% achieved ≥20%, and 26.1% achieved ≥30%. Additionally, 73% of participants with prediabetes at baseline achieved normal blood glucose at week 48 after treatment with CT-388 at 24 mg, compared to 7.5% in the placebo group.

Treatment was well-tolerated during the study – most gastrointestinal-related adverse events were mild to moderate, consistent with other incretin-class medications. Discontinuation due to adverse events was low, with only 5.9% of the CT-388 arm and 1.3% of the placebo arm dropping out of the study.

Genentech has also announced plans to present full results from the study at an upcoming medical congress. Another phase 2 investigation of CT-388 is currently ongoing, and Genentech plans to roll out the phase 3 clinical trial program at some point in Q1 2026.

Genentech. Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity. 

. January 27, 2026. Accessed January 27, 2026. 

https://www.businesswire.com/news/home/20260126768216/en/Genentech-Announces-Positive-Phase-II-Results-for-Its-Dual-GLP-1GIP-Receptor-Agonist-CT-388-in-People-Living-With-Obesity

Carmot Therapeutics, Inc. A Study of CT-388 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity. ClinicalTrials.gov Identifier: NCT06525935. Updated January 8, 2026. Accessed January 27, 2026. 

https://www.clinicaltrials.gov/study/NCT06525935

Articles

Genentech announced promising results from the phase 2 CT388-103 trial, evaluating CT-388, a dual GLP-1/GIP receptor agonist, for obesity treatment. The trial demonstrated significant weight loss and a favorable safety profile, supporting progression to phase 3 trials. Conducted as a multi-center, randomized, double-blind, placebo-controlled study, it involved 469 participants. CT-388 showed a dose-response relationship, achieving up to 22.5% placebo-adjusted weight loss. The highest dose led to substantial weight reduction and improved blood glucose levels in prediabetic patients. Adverse events were mostly mild to moderate.

The investigational dual GLP-1/GIP receptor agonist resulted in substantial weight loss without plateau after 48 weeks in patients with obesity.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Genentech Reports Positive Results from Phase 2 Trial of CT-388 in Obesity

Frances Lee, MD, is an assistant professor of medicine in the division of liver diseases at Mount Sinai.

Explore the complex relationship between pruritus, fatigue, and bone health in patients with primary biliary cholangitis (PBC).

Key Symptoms of PBC- Fatigue, Pruritus, and Bone Health

Explore expert insights on primary biliary cholangitis, focusing on symptoms, treatment innovations, and emerging clinical data for effective patient management.

An Overview of PBC Pathophysiology, Severity, and Burden

Proteomic fragmentation may explain reduced allergenicity and point to a safer substrate for peanut oral immunotherapy compared with current options, new data suggests.


Food Allergy

How Autoclaving Alters Peanut Allergenicity, OIT Potential, With Casey Cohen, PhD

Learn how to set expectations, prevent flares, and choose among advanced topical therapies for pediatric atopic dermatitis and psoriasis.

Video Series

Proactive Flare Prevention and Practical Use of Advanced Pediatric Topicals

Daniel M. Siegel, MD, is a clinical professor of dermatology at SUNY Downstate Health Sciences University, New York, and is the former president and honorary member of the American Academy of Dermatology (AAD).

Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

Tips on Billing Issues in Dermatology Practices, With Daniel Siegel, MD

In this interview, Siegel highlights key points presented in his Maui Derm 2026 talk, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

Discussing Billing Challenges in Dermatology, With Daniel Siegel, MD

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

An audio recap of the top 5 stories in healthcare news from the week of 01/18-01/24.

HCPLive 5 Stories in Under 5: Week of 01/18

Henry Lim, MD, is the senior vice president of academic programs at Henry Ford Health. He previously served as chair of the department of dermatology.

This interview with Lim highlights knowledge gaps examined by an international expert panel reviewing existing literature on dermatologic disease in skin of color.

Expert Consensus on Knowledge Gaps in Dermatology for Skin of Color, With Henry Lim, MD

Stay updated with the latest healthcare breakthroughs, including new phase 2/3 data and updated asthma guidelines, in this week’s essential news roundup.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

The HCPFive: Top News for Healthcare Providers from the Week of 01/18

Mauro D'Amato, PhD, is Ikerbasque Research Professor and head of the Gastrointestinal Genetics Lab at CIC bioGUNE.

D’Amato explains his research on the biological mechanisms that control bowel movements and vitamin B1’s potential role in gut motility.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Latest News

Looking Ahead to ASH’s 68th Meeting, With President Robert Negrin, MD

Acne and Rosacea Treatment Updates for 2026, With Lawrence Eichenfield, MD

Anticipating The FDA Decision of Anaphylm for Anaphylaxis, With David Golden, MD

Exploring Exhaled Breath as a New Platform for Gut Microbiome-Based Diagnostics

Genentech Reports Positive Results from Phase 2 Trial of CT-388 in Obesity